<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">J Subst Abuse Treat</journal-id><journal-id journal-id-type="iso-abbrev">J Subst Abuse Treat</journal-id><journal-id journal-id-type="pmc-domain-id">319</journal-id><journal-id journal-id-type="pmc-domain">nihpa</journal-id><journal-title-group><journal-title>Journal of substance abuse treatment</journal-title></journal-title-group><issn pub-type="ppub">0740-5472</issn><issn pub-type="epub">1873-6483</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>NIHPA Author Manuscripts</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC6039975</article-id><article-id pub-id-type="pmcid-ver">PMC6039975.1</article-id><article-id pub-id-type="pmcaid">6039975</article-id><article-id pub-id-type="pmcaiid">6039975</article-id><article-id pub-id-type="manuscript-id">NIHMS975411</article-id><article-id pub-id-type="pmid">29910015</article-id><article-id pub-id-type="doi">10.1016/j.jsat.2018.06.001</article-id><article-id pub-id-type="manuscript-id-alternative">NIHMS975411</article-id><article-id pub-id-type="manuscript-id-alternative">NIHPA975411</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Developing an opioid use disorder treatment cascade: A review of
quality measures</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Williams</surname><given-names initials="AR">Arthur Robin</given-names></name><xref ref-type="aff" rid="A1">a</xref><xref ref-type="aff" rid="A2">b</xref><xref rid="FN1" ref-type="author-notes">*</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Nunes</surname><given-names initials="EV">Edward V.</given-names></name><xref ref-type="aff" rid="A1">a</xref><xref ref-type="aff" rid="A2">b</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Bisaga</surname><given-names initials="A">Adam</given-names></name><xref ref-type="aff" rid="A1">a</xref><xref ref-type="aff" rid="A2">b</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Pincus</surname><given-names initials="HA">Harold A.</given-names></name><xref ref-type="aff" rid="A1">a</xref><xref ref-type="aff" rid="A2">b</xref><xref ref-type="aff" rid="A3">c</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Johnson</surname><given-names initials="KA">Kimberly A.</given-names></name><xref ref-type="aff" rid="A4">d</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Campbell</surname><given-names initials="AN">Aimee N.</given-names></name><xref ref-type="aff" rid="A1">a</xref><xref ref-type="aff" rid="A2">b</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Remien</surname><given-names initials="RH">Robert H.</given-names></name><xref ref-type="aff" rid="A5">e</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Crystal</surname><given-names initials="S">Stephen</given-names></name><xref ref-type="aff" rid="A6">f</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Friedmann</surname><given-names initials="PD">Peter D.</given-names></name><xref ref-type="aff" rid="A7">g</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Levin</surname><given-names initials="FR">Frances R.</given-names></name><xref ref-type="aff" rid="A1">a</xref><xref ref-type="aff" rid="A2">b</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Olfson</surname><given-names initials="M">Mark</given-names></name><xref ref-type="aff" rid="A1">a</xref><xref ref-type="aff" rid="A2">b</xref></contrib></contrib-group><aff id="A1">
<label>a</label>Columbia University Department of Psychiatry, United States</aff><aff id="A2">
<label>b</label>New York State Psychiatric Institute, United States</aff><aff id="A3">
<label>c</label>New York-Presbyterian Hospital, United States</aff><aff id="A4">
<label>d</label>University of South Florida Department of Mental Health Law and Policy, United
States</aff><aff id="A5">
<label>e</label>HIV Center for Clinical and Behavioral Studies, Columbia University,
United States</aff><aff id="A6">
<label>f</label>Institute for Health, Health Care Policy and Aging Research,
Rutgers, United States</aff><aff id="A7">
<label>g</label>Department of Medicine, University of Massachusetts-Baystate and
Baystate Health, United States</aff><author-notes><corresp id="FN1"><label>*</label>Corresponding author at: Division on Substance Use
Disorders, Columbia University Medical Center, New York State Psychiatric
Institute, 1051 Riverside Drive Unit #66, Office 3714, NY, NY 10032,
United States. <email>aw2879@cumc.columbia.edu</email> (A.R. Williams)</corresp><fn fn-type="COI-statement" id="FN2"><p><bold>Conflicts of interest</bold></p><p>Dr. Nunes received medication or software for research studies from Alkermes and
Reckitt-Benckiser. Dr. Bisaga received medication, extended-release naltrexone,
for NIH funded research studies from Alkermes. Dr. Friedmann reports having
received study medication in-kind from Alkermes and served on their Scientific
Advisory Board. He also received support for training and travel from Braeburn,
and served as an expert consultant in legal proceedings for Endo
Pharmaceuticals. All remaining authors report no financial relationships with
commercial interests.</p></fn></author-notes><pub-date pub-type="epub"><day>02</day><month>6</month><year>2018</year></pub-date><pub-date pub-type="ppub"><month>8</month><year>2018</year></pub-date><volume>91</volume><issue-id pub-id-type="pmc-issue-id">316700</issue-id><fpage>57</fpage><lpage>68</lpage><pub-history><event event-type="nihms-submitted"><date><day>16</day><month>06</month><year>2018</year></date></event><event event-type="pmc-release"><date><day>01</day><month>08</month><year>2018</year></date></event><event event-type="pmc-live"><date><day>01</day><month>08</month><year>2018</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-06-18 04:25:16.160"><day>18</day><month>06</month><year>2024</year></date></event></pub-history><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="nihms975411.pdf"/><related-article xmlns:xlink="http://www.w3.org/1999/xlink" related-article-type="correction-forward" xml:lang="en" vol="92" page="99" journal-id="J Subst Abuse Treat" journal-id-type="nlm-ta" ext-link-type="pubmed" xlink:href="30032951"><article-title>Corrigendum to "Developing an opioid use disorder treatment cascade: A review of quality measures" [Journal of Substance Abuse Treatment 91 (2018) 57-68].</article-title><volume>92</volume><date><day>9</day><month>7</month><year>2018</year></date><fpage>99</fpage><lpage>99</lpage><source>J Subst Abuse Treat</source><pub-id pub-id-type="pmid">30032951</pub-id></related-article><abstract><sec id="S1"><title>Background</title><p id="P1">Despite increasing opioid overdose mortality, problems persist in the
availability and quality of treatment for opioid use disorder (OUD). Three
FDA-approved medications (methadone, buprenorphine, and naltrexone) have
high quality evidence supporting their use, but most individuals with OUD do
not receive them and many experience relapse following care episodes.
Developing and organizing quality measures under a unified framework such as
a Cascade of Care could improve system level practice and treatment
outcomes. In this context, a review was performed of existing quality
measures relevant to the treatment of OUD and the literature assessing the
utility of these measures in community practice.</p></sec><sec id="S2"><title>Methods</title><p id="P2">Systematic searches of two national quality measure clearinghouses
(National Quality Forum and Agency for Healthcare Research and Quality) were
performed for measures that can be applied to the treatment of OUD. Measures
were categorized as structural, process, or outcome measures. Second stage
searches were then performed within Ovid/Medline focused on published
studies investigating the feasibility, reliability, and validity of
identified measures, predictors of their satisfaction, and related clinical
outcomes.</p></sec><sec id="S3"><title>Results</title><p id="P3">Seven quality measures were identified that are applicable to the
treatment of OUD. All seven were process measures that assess patterns of
service delivery. One recently approved measure addresses retention in
medication-assisted treatment for patients with OUD. Twenty-nine published
studies were identified that evaluate the quality measures, primarily
focused on initiation and engagement in care for addiction treatment
generally. Most measures and related studies do not specifically incorporate
the evidence base for the treatment of OUD or assess patient level outcomes
such as overdose.</p></sec><sec id="S4"><title>Conclusion</title><p id="P4">Despite considerable progress, gaps exist in quality measures for OUD
treatment. Development of a unified quality measurement framework such as an
OUD Treatment Cascade will require further elaboration and refinement of
existing measures across populations and settings. Such a framework could
form the basis for applying strategies at clinical, organizational, and
policy levels to expand access to quality care and reduce opioid-related
mortality.</p></sec></abstract><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>